American Heart Association: Rejected and Unfilled Prescriptions for New, More Expensive Cholesterol Drugs Tied to Higher Heart, Stroke Risk
July 23, 2019
July 23, 2019
DALLAS, Texas, July 23 -- The American Heart Association issued the following news release:
* * *
- Prescriptions for the newest - but more expensive - cholesterol-lowering drugs called PCSK9 inhibitors that are not covered by insurance companies or unfilled by patients are related to higher risk of cardiovascular problems for high risk patients.
- High co-payments may make patients less likely to fill prescriptions, even if insurers approve them.
* * *
- Prescriptions for the newest - but more expensive - cholesterol-lowering drugs called PCSK9 inhibitors that are not covered by insurance companies or unfilled by patients are related to higher risk of cardiovascular problems for high risk patients.
- High co-payments may make patients less likely to fill prescriptions, even if insurers approve them.